Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy ; volume:32 ; number:6 ; day:22 ; month:5 ; year:2024 ; pages:1-13 ; date:6.2024
Supportive care in cancer ; 32, Heft 6 (22.5.2024), 1-13, 6.2024

Creator: Jin, Shan-xiu
Liu, Bo-Na
Ji, Hong-juan
Wu, Jing-ran
Li, Bao-lei
Gao, Xiao-li
Li, Na
Zheng, Zhen-dong
Du, Cheng

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00520-024-08525-z

URN: urn:nbn:de:101:1-2410100728501.744537895859

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Jin, Shan-xiu
Liu, Bo-Na
Ji, Hong-juan
Wu, Jing-ran
Li, Bao-lei
Gao, Xiao-li
Li, Na
Zheng, Zhen-dong
Du, Cheng
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Related objects

Reset password